Key Takeaway: Precision BioSciences reported positive results from its Phase 1 ELIMINATE-B trial for PBGENE-HBV, aimed at treating Hepatitis B. The trial showed substantial antiviral activity in all patients of Cohort 1, with the best responses reaching 47-69%. Safety data for Cohort 2 was also announced, indicating ongoing progress in the trial.
Price reaction · baseline $4.81 (2025-08-06 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
-5%
Market Sentiment Analysis
POSITIVE FACTORS
Rapid progress in Phase 1 ELIMINATE-B trial.
Substantial antiviral activity demonstrated in all Cohort 1 patients.
Best responses achieving 47-69% efficacy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Continued rapid progress with Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV for Hepatitis B; Announced safety and efficacy for Cohort 1 and safety data for Cohort 2 – PBGENE-HBV demonstrated substantial antiviral activity in all Cohort 1 patients, with best responses achieving a 47-69%
Frequently Asked Questions
What is the ELIMINATE-B trial?
The ELIMINATE-B trial is a Phase 1 study evaluating PBGENE-HBV for Hepatitis B.
What results were reported for Cohort 1?
Cohort 1 demonstrated substantial antiviral activity, with best responses of 47-69%.
What safety data was announced for Cohort 2?
Safety data for Cohort 2 was announced, indicating ongoing trial progress.